PROGAV 2.0 VALVE FX410T

MAUDE Adverse Event Report

MAUDE data represents reports of adverse events involving medical devices. This maude entry was filed from a company representative,foreig report with the FDA on 2020-03-19 for PROGAV 2.0 VALVE FX410T manufactured by Christoph Miethke Gmbh & Co. Kg.

Event Text Entries

[188561305] Investigation: visual inspection: in the first step of our investigations, an optical control is carried out. It is checked whether any defects, deformations or other noticeable irregularities can be identified. Permeability test: to proof the penetrability of the valve we have carried out penetrability tests. These tests are carried out at a calculated hydrostatic high (open pressure of the valves + 30cmh2o) in horizontal direction of flow. Adjustment test: the adjustment test is used to ensure that the progav 2. 0 can be adjusted to all pressure levels. The tests are carried out with the standard progav 2. 0 checkmate and measurement tool. The valve is adjusted from 0 to 20 cmh2o and down again in increments of 5 cmh2o. Braking force and brake function test: to measure the braking force, we tested the progav 2. 0 valve with a braking force apparatus. Here it is measured how much force must be exerted on the housing to release the rotor to adjust the valve by the integrated magnet of the braking force apparatus. Results: no significant deformations or damage of the valves were detected during the visual inspection. Next, we tested the permeability of valve. The progav 2. 0 was permeable and operating within specifications. Additionally, we tested the adjustability as well as the brake functionality and brake force of the progav 2. 0 valve. The valve operated as expected and met all specifications. Finally, we have dismantled the valve. Inside the valve, we have found visible slight build-up of substances (likely protein). Based on our investigation, we are unable to substantiate the claim of occlusion. At the time of our investigation, the valve was shown to be permeable. At the time of the investigation, we are not able to determine how the functional impairment mentioned above occurred in the past. However, we suspect that the significant deposits found inside the valve have led to the functional impairment in the past. We can exclude a defect at the time of release. The shunt system met all specifications of the final inspection when released from christoph miethke (b)(4).
Patient Sequence No: 1, Text Type: N, H10


[188561306] It was reported that there is an issue with valve. The reporter indicated that a post-operative valve has a blockage. The device was explanted. Additional event details and patient information has not provided, however, have been requested.
Patient Sequence No: 1, Text Type: D, B5


MAUDE Entry Details

Report Number3004721439-2020-00066
MDR Report Key9856966
Report SourceCOMPANY REPRESENTATIVE,FOREIG
Date Received2020-03-19
Date of Report2020-03-19
Date of Event2019-12-06
Date Mfgr Received2020-02-21
Date Added to Maude2020-03-19
Event Key0
Report Source CodeManufacturer report
Manufacturer LinkY
Number of Patients in Event0
Adverse Event Flag3
Product Problem Flag3
Reprocessed and Reused Flag3
Reporter OccupationOTHER HEALTH CARE PROFESSIONAL
Health Professional3
Initial Report to FDA3
Report to FDA3
Event Location3
Manufacturer ContactJOERG KNEBEL
Manufacturer Street2 ULANENWEG
Manufacturer CityPOTSDAM D, 14469
Manufacturer CountryGM
Manufacturer Postal14469
Manufacturer G1CHRISTOPH MIETHKE GMBH & CO. KG
Manufacturer Street2 ULANENWEG
Manufacturer CityPOTSDAM D, 14469
Manufacturer CountryGM
Manufacturer Postal Code14469
Single Use3
Previous Use Code3
Event Type3
Type of Report3

Device Details

Brand NamePROGAV 2.0 VALVE
Generic NameHYDROCEPHALUS MANAGEMENT
Product CodeJXG
Date Received2020-03-19
Returned To Mfg2020-03-03
Model NumberFX410T
Catalog NumberFX410T
Lot Number20042933
OperatorHEALTH PROFESSIONAL
Device AvailabilityR
Device Eval'ed by MfgrY
Device Sequence No1
Device Event Key0
ManufacturerCHRISTOPH MIETHKE GMBH & CO. KG
Manufacturer Address2 ULANENWEG POTSDAM D, 14469 GM 14469


Patients

Patient NumberTreatmentOutcomeDate
101. Required No Informationntervention 2020-03-19

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.